China/Hong Kong Pharma Trade Set To Intensify

25 August 1997

China's shift from state planning to the free market has led to adramatic strengthening of Hong Kong's economy, and observers now believe prospects for intensified cooperation in medicines between the two are good, especially because of HK's role as a bridge to the world outside China.

Pharmaceutical trade between the two is buoyant already, but HK focuses on international trade and its production capacity is limited. It has 400 dealers trading western drugs internationally, 350 traders in health care goods, 150 drug wholesalers and about 1,500 drugstores.

HK drug imports are said to be rising 15% a year and topped HK$10 billion ($1.3 billion) in 1996. Exports are also growing fast, reaching about HK$9 billion last year. China is HK's main medicines supplier and the largest consumer of HK-imported drugs, but transit trade volume now accounts for 75% of imports and 90% of exports between them.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight